Inhaled drugs are critical for the treatment of inflammatory airway diseases such as chronic obstructive pulmonary disease (COPD). To develop better therapeutics for pulmonary disease it is of potential importance to understand molecular mechanisms of local biotransformation in the lung. Alveolar epithelial type II (ATII) cells have a key role in homeostasis in the lung, but little is known about expression patterns of genes encoding cytochrome P450 (CYP) enzymes in ATII cells. In addition, alteration of CYP gene expression has not been fully defined in COPD. We previously established a method to purify ATII cells from the adult human lung using fluorescence-activated cell sorting. By employing this technique we determined gene expression patterns of 14 CYP enzymes in ATII cells from nonsmokers (n = 4) and smokers (n = 4), both having normal pulmonary function.
| INTRODUCTION
Inhaled drugs such as long-acting beta-agonists, long-acting antimuscarinic antagonists, and inhaled corticosteroids are used as therapeutic options for patients with chronic obstructive pulmonary disease (COPD) 1 which is a leading cause of morbidity, mortality, and health-care costs worldwide. 2 In addition to the current treatments, recent advances indicate that next-generation inhaled drugs including kinase inhibitors have been developed for inflammatory airway diseases. 3 This is because therapeutic agents that are directly administered to the lungs have at least 2 substantial merits: (i) the rapid onset of action by direct delivery to the airways and (ii) the local high concentration to minimize the systemic adverse effects. Susceptibility to drug metabolism in the target organ has the possibility of reducing effective drug concentration and producing metabolites that give rise to patient safety risk or have pharmacological activity. Additionally, a novel candidate drug may beneficially inhibit an enzyme responsible for producing potentially toxic metabolites of an inhaled molecule that may be present in, for example, tobacco smoke. Thus development of inhaled drugs ideally requires in-depth knowledge of drug biotransformation in the lung.
Expression and functional activity of drug-metabolizing enzymes including cytochrome P450 (CYP) enzymes can be altered in diseases of the liver which is the vital organ for metabolisms of orally administered therapeutics. 4 The human pulmonary tissue also expresses a wide range of CYP enzymes to metabolize a great variety of inhaled xenobiotics and toxicants, but the expression pattern of lung CYPs substantially differ from metabolisms in the liver. [5] [6] [7] A recent study using a comprehensive expression analysis for genes encoding membrane transporters and phase I and II drug-metabolizing enzymes indicated that these gene expressions were not significantly altered in lung tissues from patients with COPD compared to healthy subjects. 8 However, given previous reports indicating different expres- In this study, we aimed to determine expression patterns of 14 genes encoding CYP enzymes in human ATII cells using a fluorescence-activated cell sorting (FACS)-based method for purifying ATII cells from human lung tissues. 13 In addition, we sought to determine CYP enzymes that were differentially expressed in ATII cells of patients with COPD.
| MATERIALS AND METHODS

| Patients and human lung tissue preparation
The Ethics Committees at Tohoku University School of Medicine and at Japanese Red Cross Ishinomaki Hospital approved this study.
The experiments conformed to the principles set out in the WMA Declaration of Helsinki. All subjects gave their informed consent.
Patients' characteristics are shown in Table 1 according to the manufacturer's instruction. The relative expression levels of the specific mRNAs were calculated using the DDC t method.
| Preparation of human hepatocytes
| Statistics
All data are presented as the mean AE SEM. Statistical analyses were conducted using GraphPad Prism (GraphPad Software). To compare 2 datasets, 2-tailed unpaired t-test was applied. Correlation was evaluated by Spearman's rank-order correlation. P < .05 was considered significant.
| RESULTS AND DISCUSSION
We firstly sought to determine expression patterns of genes encoding 14 CYP enzymes in human ATII cells by comparing to those in human hepatocytes that are major cell-types metabolizing orally or systemically administered drugs. We isolated ATII cells from non-COPD patients (nonsmokers, n = 4; smokers, n = 4) whose tissues were pathologically confirmed not to have overt inflammation or fibrotic changes. Among 14 CYP genes tested, CYP1A2 and CYP3A4 mRNAs were not detected in the isolated ATII cells (data not shown). These 2 enzymes are major CYP isoforms in human liver. 14 The data presented here agrees previous studies showing no or very low expressions of CYP1A2 and CYP3A4 mRNAs in human lung tissue. 8, 15 In the remaining 12 CYP genes only CYP1B1 mRNA significantly increased in ATII cells compared to hepatocytes (Figure 1 ).
CYP1B1 metabolically activates polycyclic aromatic hydrocarbons
(PAHs) such as Benzo[a]pyrene contained in tobacco smoke to ultimately generate mutagenic and carcinogenic compounds. 16 Considering recent studies using rat ATII cells indicated that Although other CYP genes were found to be at approximately 10-fold (3A5, 2J2), 100-fold (2C19, 1A1, 2E1, 2D6) or 1000-fold (2C8, 2A6, 2B6, 2C9) higher levels in hepatocytes than in ATII cells (Figure 1) , there was only 2-fold difference in the expression level of CYP2U1 between the 2 cell-types. This is of particular interest since
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Comparison of mRNA expression of 12 CYP enzymes in ATII cells between smokers without COPD (n = 4) and patients with COPD (n = 3). n indicated the number of individuals. Each dot represents an individual and bars indicate the mean AE SD. Two-tailed unpaired t-test was used for statistics COPD. Although the sample number was relatively small, CYP2C19
mRNA in ATII cells of COPD patients showed 3.0-fold higher levels than that in ATII cells from smokers ( Figure 2 ). In contrast, CYP2J2 mRNA in COPD subjects was half the level of that in smokers (Figure 2 ). These differences were not identified when whole-lung tissues from smokers and COPD patients were used for analysis.
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CYP2C19 is a major phase 1 enzyme in the liver and is involved in metabolism of a wide range of drugs such as proton pomp inhibitors and anticancer agents. 23 Although genetic polymorphisms are translated to the poor metabolism of these drugs in some individuals, recent studies have supported the idea that factors regulating CYP2C19 transcription are also important for its pharmacokinetics. 24 One such transcription factor responsible for transactivation of CYP2C19 is forkhead box protein A3 or FOXA3. 25 The reason for the higher expression of CYP2C19 in ATII cells from COPD patients (Figure 2 ) may be due to the upregulation of FOXA3 in inflamed airway epithelium of these patients. 26 This data provides a rationale for the investigation of FOXA3 in the transregulation of CYP2C19 gene expression in COPD.
CYP2J2 is expressed in extrahepatic tissues, especially in the heart, but also in the lung 19 and is known to metabolize endogenous arachidonic acids for generating epoxyeicosatrienoic acids (EETs) 27 as well as exogenous diverse therapeutics such as antihistamine drugs. 28 Recent studies using mouse models indicate that CYP2J2-mediated EETs reduce excessive inflammation in the lung and liver. 29, 30 Thus the reduced CYP2J2 expression in COPD ATII cells may contribute to proinflammatory conditions in disease.
In summary, we clarified expression patterns of genes encoding cytochrome P450 enzymes in alveolar epithelial type II cells (ATII) in human lung and found higher expression of CYP1B1 mRNA in ATII cells than in primary hepatocytes. Moreover using the cell-type-specific approach we for the first time demonstrated that CYP2C19 and CYP2J2 mRNA expressions were altered in ATII cells in COPD.
These CYP enzymes are known to be able to metabolize kinase inhibitors. 31 Taken together with promising roles of kinase inhibitors for the treatment of COPD, 32 our results lead to a new insight into the altered expression of CYP enzymes in the alveolar epithelium in inflammatory airway diseases.
